Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.
D000179:Acrylates / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D000179:Acrylates; D005047:Etoposide; D011034:Podophyllotoxin